Market Research Logo

Global Markets for Infectious Disease Treatments

The global market for infectious disease diagnostic, vaccine, and treatment products reached $108.4 billion in 2015. The market should reach $126.2 billion in 2016 and $183.2 billion in 2021, demonstrating a compound annual growth rate (CAGR) of 7.7% from 2016 to 2021.

This report provides:
An overview of the global market for infectious disease treatments, with a focus on the growth in demand for newer pharmaceutical treatments, vaccines, and environmental products.
Analyses of global market trends, with data from 2014, estimates for 2015, and projections of compound annual growth rates (CAGRs) through 2021.
Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans.
Examination of technological developments, future trends, and emerging opportunities.
Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region.
A relevant patent analysis.
Profiles of major players in the field of infectious disease treatments.


SCOPE OF REPORT

The market report organizes information from diverse sources into a cohesive unit that includes an overview, global implications of infectious diseases, infectious diseases by type, treatment and prevention, emerging pharmaceutical and diagnostic products and an applicable patents section. Information is organized by type of infectious disease (i.e., bacterial, viral, parasitic) and appropriate treatments, both current and anticipated.

CHAPTER 1 Introduction
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THE STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGIES AND INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 SUMMARY
SUMMARY TABLE GLOBAL MARKET FOR INFECTIOUS DISEASES DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET SHARE FOR INFECTIOUS DISEASE DIAGNOSTIC, VACCINE AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
CHAPTER 3 OVERVIEW OF THE GLOBAL STATE OF INFECTIOUS DISEASE DIAGNOSIS, VACCINES AND TREATMENT
TOP GLOBAL CAUSES OF DEATH
TABLE 1 GLOBAL PERCENTAGE OF DEATHS BY TYPE OF DISEASE, CAUSE, INCOME LEVEL, 2012* (%)
MAJOR INFECTIOUS DISEASES
TABLE 2 SELECTED WORLDWIDE MAJOR INFECTIOUS DISEASES, 2013*
(NUMBER OF CASES, TREATMENT OPTIONS)
HISTORICAL IMPACT OF INFECTIOUS DISEASES
LEADING CAUSES OF GLOBAL DEATHS
Transmission of Infectious Diseases
LINKING INFECTIOUS DISEASE TO CANCER
TREATMENTS FOR INFECTIOUS DISEASES
PREVENTION
VACCINATION
WHO Global Vaccination Action Plan
FIGURE 1 GLOBAL IMMUNIZATION COVERAGE, 2014 (%)
Challenges to Meet WHO Guidelines
GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET
TYPES OF DIAGNOSTIC TESTING
FLUORESCENT IMMUNOASSAY (FIA)
Direct Fluorescent Antibody Testing (FA)
Indirect Fluorescent Antibody Testing (IFA)
ENZYME IMMUNOASSAY (EIA)
Basic EIA
Enzyme-Linked Immunosorbent Assay (ELISA)
GENE PROBE ANALYSIS
Polymerase Chain Reaction Amplification (PCR)
Nucleic Acid Amplification Test (NAT)
Transcription-Mediated Amplification (TMA)
Nucleic Acid Sequence-Based Amplification (NASBA)
GLOBAL MARKET FOR INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS
TABLE 3 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
GLOBAL INFECTIOUS DISEASE VACCINE MARKET
TABLE 4 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
GLOBAL INFECTIOUS DISEASE PHARMACEUTICAL MARKET
TABLE 5 GLOBAL MARKET FOR HUMAN INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
VACCINE OPPORTUNITIES
CHILDHOOD DISEASES
GLOBAL HUMANITARIAN AGENCIES
PHARMACEUTICAL OPPORTUNITIES
THE EMERGENCE OF GENE THERAPY
MERGERS AND ACQUISITIONS
TABLE 6 SELECTED MERGERS AND ACQUISITIONS, 2012 TO 2015 ($ MILLIONS)
CHAPTER 4 VACCINES - THE PRESENT AND THE FUTURE
VACCINES AND PATENTS
MARKET FOR HUMAN INFECTIOUS DISEASE VACCINES
TABLE 7 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINE PRODUCTS, THROUGH 2021 ($ MILLIONS)
TABLE 8 GLOBAL MARKET FOR INFECTIOUS DISEASE VACCINES BY ISEASE,
THROUGH 2021 ($ MILLIONS)
TYPES OF VACCINES
LIVE ATTENUATED VACCINE
INACTIVATED VACCINE
Acellular/Subunit Vaccines
IMMUNITY
INNATE IMMUNITY
ACQUIRED IMMUNITY
The Activity of T Cells
Acquired Immunity - Cell-Mediated Response
LASTING IMMUNITY
VIRAL DISEASES PREVENTED BY VACCINE
TABLE 9 VIRUSES, THE DISEASES THEY CAUSE, AND AVAILABLE VACCINES
BACTERIAL DISEASES PREVENTED BY VACCINE
TABLE 10 BACTERIA, THE DISEASES THEY CAUSE, AND AVAILABLE
VACCINES
VACCINATION SCHEDULES FOR CHILDREN IN THE U.S.
TABLE 11 IMMUNIZATION SCHEDULE FOR CHILDREN FROM BIRTH TO 6 MONTHS IN THE U.S.
TABLE 12 IMMUNIZATION SCHEDULE FOR CHILDREN FROM 12 MONTHS, TO 4 YEARS TO 6 YEARS IN THE U.S.
TABLE 13 IMMUNIZATION SCHEDULE FOR CHILDREN AND ADOLESCENTS FROM 7 YEARS TO 18 YEARS IN THE U.S.
CONCERNS REGARDING VACCINATION IN CHILDHOOD
NUMBER OF INOCULATIONS
RECOGNIZING IMMUNE RESPONSE
IMMUNIZATION AND WEAKENED OR ALTERED IMMUNE SYSTEMS
HEPATITIS B VACCINATIONS THROUGH WHO GUIDELINES
VACCINE PRODUCTION
FIGURE 2 VACCINE MANUFACTURING PROCESS
VACCINE MANUFACTURERS
FIGURE 3 GLOBAL VACCINE MANUFACTURING MARKET, 2014 (%)
CHANGES IN MANUFACTURING LANDSCAPE
TOP-SELLING VACCINES OF 2014
TABLE 14 TOP-SELLING INFECTIOUS DISEASE VACCINES WITH APPLICATION, MANUFACTURER AND REVENUE, 2014
GLOBAL VACCINATION EFFORTS
REGIONAL ANALYSIS
TABLE 15 REGIONAL MARKETS FOR VACCINES, THROUGH 2021 ($ MILLIONS)
FIGURE 4 REGIONAL MARKET SHARE FOR VACCINES, 2016 AND 2021 (%)
THE AMERICAS
TABLE 16 AMERICAS MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
EMRA
TABLE 17 EMRA MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
ASIA
TABLE 18 ASIAN MARKET FOR INFECTIOUS DISEASE VACCINES BY REGION, THROUGH 2021 ($ MILLIONS)
TRENDS IN VACCINE DEVELOPMENT
ADJUVANT DEVELOPMENT
COMBINATION VACCINES
INHALED OR INTRANASAL VACCINE ADMINISTRATION
NEED FOR RAPID RESPONSE TIMES
Real-Time Detection
CHAPTER 5 VIRAL INFECTIOUS DISEASES
GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
TABLE 19 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
PATENT PROTECTION
TABLE 20 PATENT EXPIRY BY PRODUCT, INDICATION, MANUFACTURER AND DATE OF PATENT EXPIRY
HEPATITIS B AND C
MARKET FOR HBV AND HCV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
TABLE 21 GLOBAL MARKET FOR HEPATITIS DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
DIAGNOSIS
TABLE 22 GLOBAL MARKET SHARE FOR HEPATITIS B AND C DIAGNOSTIC PRODUCT BY TYPE OF TEST AND REVENUES, 2015 ($ MILLIONS/%)
TABLE 23 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HEPATITIS B AND C BY BRAND NAME AND MANUFACTURER, 2015
Automated Infectious Disease Testing for Hepatitis
TREATMENT MARKET
TABLE 24 GLOBAL MARKET FOR HEPATITIS B AND C TREATMENT MANUFACTURER MARKET STANDING BY REVENUES, 2015 ($ MILLIONS/RANK)
FIGURE 5 GLOBAL MARKET SHARE FOR TOP PHARMACEUTICAL MANUFACTURERS IN THE HEPATITIS MARKET, 2015 (%)
TABLE 25 PHARMACEUTICALS FOR THE TREATMENT OF HEPATITIS B AND C, 2015
NEWEST PHARMACEUTICALS TO TREAT HBV AND HCV
Additional Competitor
MARKET FOR DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS TO TREAT HBV AND HCV
TABLE 26 GLOBAL MARKET FOR HBV AND HCV PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
RISK FACTORS
GEOGRAPHICAL DISTRIBUTION
HERPES SIMPLEX VIRUS
TABLE 27 GLOBAL MARKET FOR HSV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
INCIDENCE
DIAGNOSIS
TABLE 28 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HSV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
TREATMENT
TABLE 29 DRUGS USED TO TREAT HSV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
HIV/AIDS
TABLE 30 GLOBAL MARKET FOR HIV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
RISK FACTORS
INCIDENCE/MORTALITY
ANTIRETROVIRAL THERAPY (ART)
HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART)
TABLE 31 COMBINATION DRUGS APPROVED FOR HAART
HAART Failure
Mega-HAART
"TREATMENT FOR ALL" WHO PROGRAM
COUNT <800 CELLS/MEDICATIONS
Pre-Exposure Prophylaxis
CLINICAL TRIALS FOR HIV VACCINE AND MEDICATIONS
HUMAN PAPILLOMAVIRUS
TABLE 32 GLOBAL MARKET FOR HPV DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
HPV AND CANCER
TABLE 33 CANCERS LINKED TO HPV INFECTION, BY TYPE AND PERCENT OF FREQUENCY
INCIDENCE
SYMPTOMS
DIAGNOSIS
TABLE 34 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF HPV BY BRAND NAME, TYPE AND MANUFACTURER, 2015
TREATMENT
TABLE 35 DRUGS USED TO TREAT HPV BY BRAND NAME, GENERIC NAME AND MANUFACTURER
INFLUENZA A AND B
VACCINE
TREATMENT
CHILDHOOD DISEASES
MEASLES
MUMPS
POLIO
VIRAL PNEUMONIA
Treatment
ROTAVIRUS
DEHYDRATION
ZINC
RSV
SYMPTOMS
DIAGNOSTIC PRODUCTS
TABLE 36 RSV DIAGNOSTIC PRODUCTS BY BRAND NAME, MANUFACTURER AND TYPE, 2015
VIRAL DIAGNOSTIC PRODUCTS
TABLE 37 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
VIRAL PHARMACEUTICAL PRODUCTS
TABLE 38 GLOBAL MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
REGIONAL ANALYSIS
TABLE 39 REGIONAL MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
FIGURE 6 REGIONAL MARKET SHARE FOR VIRAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
TABLE 40 REGIONAL MARKET FOR VIRAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
TABLE 41 REGIONAL MARKET FOR VIRAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
AMERICAS
Hepatitis B in the U.S.
Hepatitis C in the U.S.
Market for Viral Infectious Disease Products in the Americas
TABLE 42 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 43 AMERICAS MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
EMRA
Hepatitis C
Hepatitis in Africa
Hepatitis in Russia, Eurasia
Russian Pharmaceutical Regulations
Market for Viral Infectious Disease Diagnostic Products
TABLE 44 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 45 EMRA MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
ASIA
Hepatitis in Asian Region
TABLE 46 CURRENTLY USED HEPATITIS DRUGS IN THE SOUTHEAST ASIAN REGION, BY PERCENT OF USE, 2012*
Hepatitis in Japan
Hepatitis in China
Hepatitis in India
HIV in Japan
HIV in India
HIV in China
TABLE 47 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 48 ASIAN MARKET FOR VIRAL INFECTIOUS DISEASE PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
CHAPTER 6 BACTERIAL INFECTIOUS DISEASES AND THE SPECTER OF
ANTIBIOTIC RESISTANCE
NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES
TABLE 49 NEGLECTED TROPICAL BACTERIAL INFECTIOUS DISEASES MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS
TABLE 50 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTICS
TABLE 51 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTICS, THROUGH 2021 ($ MILLIONS)
MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS
TABLE 52 GLOBAL MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICALS, THROUGH 2021 ($ MILLIONS)
NOTABLE BACTERIAL DISEASES
SEXUALLY TRANSMITTED DISEASES
Chlamydia
INCIDENCE
DIAGNOSTIC PROCEDURES
TABLE 53 CURRENTLY AVAILABLE CHLAMYDIA TESTS BY BRAND NAME, TYPE AND MANUFACTURER, 2015
TREATMENTS
TABLE 54 CURRENT MEDICATIONS USED TO TREAT CHLAMYDIA
Gonorrhea
Diagnostic Product Market
TABLE 55 GONORRHEA DIAGNOSTIC PRODUCT AND MANUFACTURERS
Treatment Market
TABLE 56 MAJOR GONORRHEA TREATMENT MANUFACTURERS AND PRODUCTS
Syphilis
TABLE 57 STAGES OF SYPHILIS
Risk Factors
Incidence
Diagnostic Products
TABLE 58 CURRENT DIAGNOSTIC PRODUCTS FOR DETECTION OF SYPHILIS BY BRAND NAME, TYPE AND MANUFACTURER, 2012
TREATMENTS
BACTERIAL PNEUMONIA
Treatment
CORYNEBACTERIUM DIPHTHERIAE, CLOSTRIDIUM TETANI, BORDETELLA
PERTUSSIS
Diphtheria
Tetanus
Pertussis
MENINGITIS
MYCOBACTERIUM TUBERCULOSIS (TB)
TABLE 59 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Epidemiology of TB
Geographic Prevalence
TABLE 60 GLOBAL MARKET FOR TB DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS BY REGION, THROUGH 2021 ($ MILLIONS)
ANTIBIOTIC DEVELOPMENT
TABLE 61 ANTIBIOTICS: YEAR OF INTRODUCTION, YEAR OF RESISTANCE
OBSERVED, MODE OF ACTION AND TARGET SPECIES
ANTIBIOTIC RESISTANCE
MECHANISMS OF RESISTANCE
METHODS OF RESISTANCE
Beta-Lactamase Production
Importing Resistance from Other Organisms
Examples of Antibiotic-Resistant Bacteria
Alteration of Binding Sites to Circumvent Anti-Infective Effectiveness
Antibiotic Discharge
PRIMARY REASONS FOR ANTIBIOTIC RESISTANCE
Failure to Finish Antibiotic Courses
Antibiotic Overuse
Agricultural Practices
TABLE 62 ANTIBIOTICS APPROVED FOR USE IN FOOD-PRODUCING ANIMALS BY DRUG CLASS, POUNDS USED, AND PERCENTAGE OF TOTAL, 2009* (POUNDS/%)
Patient Pressure
RESISTANCE BY CLASS OF ANTIBIOTIC
TABLE 63 ANTIBIOTIC-RESISTANT ORGANISMS AND DRUG CLASSES
AFFECTED
INCIDENCES OF ANTIBIOTIC RESISTANCE
ANTIBIOTIC RESISTANCE IN EUROPE
ANTIBIOTIC RESISTANCE IN THE U.S.
MAJOR ANTIBIOTIC-RESISTANT ORGANISMS
VANCOMYCIN-RESISTANT ENTEROCOCCUS (VRE)
METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
CLOSTRIDIUM DIFFICILE (C. DIFFICILE)
REGIONAL ANALYSIS
TABLE 64 REGIONAL MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
FIGURE 7 REGIONAL MARKET SHARE FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
THE AMERICAS
STDs in the U.S.
TABLE 65 AMERICAS MARKET FOR BACTERIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Bacterial Infection Diagnostic Product Market in the Americas
TABLE 66 AMERICAS MARKET FOR BACTERIAL INFECTIOUS DISEASE DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
Bacterial Infection Pharmaceutical Market in the Americas
TABLE 67 AMERICAS MARKET FOR BACTERIAL INFECTION PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
EMRA (EUROPE, MIDDLE EAST, RUSSIA, AFRICA)
TABLE 68 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Bacterial Infectious Diseases Diagnostic Market in EMRA
TABLE 69 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
Bacterial Infectious Diseases Pharmaceutical Product Market in EMRA
TABLE 70 EMRA MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
ASIA
TABLE 71 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Bacterial Infectious Diseases Diagnostic Product Market in Asia
TABLE 72 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
Bacterial Infectious Diseases Pharmaceutical Product Market in Asia
TABLE 73 ASIAN MARKET FOR BACTERIAL INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
CHAPTER 7 PARASITIC INFECTIOUS DISEASES
NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
TABLE 74 NEGLECTED TROPICAL PARASITIC INFECTIOUS DISEASES
CLIMATE CHANGE AND VECTOR-BORNE DISEASES
MALARIA
INCIDENCES OF MALARIA
Global Risk for Malaria
CAUSES OF MALARIA
Symptoms of Malaria
GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL
TREATMENTS
TABLE 75 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
DIAGNOSIS OF MALARIA
TABLE 76 GLOBAL MARKET FOR MALARIAL DIAGNOSTIC PRODUCTS, THROUGH 2021 ($ MILLIONS)
TREATMENT OF MALARIA
TABLE 77 CURRENT PHARMACEUTICALS FOR TREATMENT OF MALARIA, WITH TREATMENT AND MANUFACTURER, 2015
TABLE 78 GLOBAL MARKET FOR MALARIAL PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
REGIONAL ANALYSIS
TABLE 79 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND HARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
FIGURE 8 REGIONAL MARKET FOR MALARIAL DIAGNOSTIC AND HARMACEUTICAL PRODUCTS, 2016 AND 2021 (%)
THE AMERICAS
TABLE 80 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Malarial Diagnostic Product Market in the Americas
TABLE 81 AMERICAS MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
Malarial Pharmaceutical Market in the Americas
TABLE 82 AMERICAS MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
EMRA
TABLE 83 EMRA MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
Malarial Diagnostic Product Market in EMRA
TABLE 84 EMRA MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
Malarial Pharmaceutical Product Market in the EMRA
TABLE 85 EMRA MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
ASIA
TABLE 86 ASIAN MARKET FOR MALARIAL DIAGNOSTIC AND PHARMACEUTICAL PRODUCTS, THROUGH 2021 ($ MILLIONS)
TABLE 87 ASIAN MARKET FOR MALARIAL DIAGNOSTIC PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 88 ASIAN MARKET FOR MALARIAL PHARMACEUTICAL PRODUCT BY REGION, THROUGH 2021 ($ MILLIONS)
TABLE 89 CURRENT AND PARASITIC PHARMACEUTICALS WITH TRADE
NAME, GENERIC NAME, MANUFACTURER AND AREA OF TREATMENT, 2014
MARKET FOR ANTIPARASITIC PHARMACEUTICALS
OPPORTUNITIES IN THE MALARIAL DISEASE MARKET
DIAGNOSTIC TESTING
CHAPTER 8 EMERGING TECHNOLOGY AND PHARMACEUTICALS
GLAXOSMITHKLINE/NOVARTIS TRANSACTION
HEPATITIS C
TABLE 90 FDA-APPROVED PHARMACEUTICALS TO TREAT HCV, 2011-2015
TABLE 91 PHARMACEUTICALS IN CLINICAL TRIALS FOR HCV, 2015
FIGURE 9 RESEARCH LANDSCAPE FOR HBV PHARMACEUTICALS BY TYPE, 2015 (%)
DENGUE VIRUS VACCINE
MALARIA
TABLE 92 PHASE II & III PIPELINE FOR MALARIAL TREATMENTS, 2015
BASILEA PHARMACEUTICA
POLYPHOR
REMPEX PHARMA
HIV
ATTACHMENT INHIBITORS
GENE MODIFICATION
PHARMACEUTICAL TREATMENT PRODUCT PIPELINE
TABLE 93 INFECTIOUS DISEASES PHARMACEUTICAL PRODUCT PIPELINE, BY DISEASE, 2015
CHAPTER 9 PATENT ANALYSIS
PATENT ANALYSIS
PATENT EXPIRATIONS
TABLE 94 U.S. PHARMACEUTICAL PATENT EXPIRY, 2010-2031
PHARMACEUTICAL PATENTS, BY PATENT NUMBER, DISEASE, COMPANY, DESCRIPTION AND APPROVAL DATE
TABLE 95 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PATENTS, JAN. 2015 TO SEPT. 2015
PATENTS ISSUED BY COMPANY
TABLE 96 INFECTIOUS DISEASES PHARMACEUTICAL AND VACCINE PRODUCT PATENTS BY COMPANY, JAN. 2015 TO SEPT. 2015 INFECTIOUS DISEASES PATENTS ISSUED, BY DISEASE
TABLE 97 PATENTS ISSUED FOR VACCINE AND TREATMENT OF NFECTIOUS DISEASES BY DISEASE, JAN. 2015 TO SEPT. 2015 (NUMBER/%)
TABLE 98 INFECTIOUS DISEASES VACCINE AND PHARMACEUTICAL PATENTS BY DISEASE ISSUED BETWEEN JAN. 2015 AND SEPT. 2015 (%)
CHAPTER 10 COMPANY DIRECTORY
ABBOTT LABORATORIES
BUSINESS OVERVIEW
TABLE 99 ABBOTT PHARMACEUTICAL PRODUCTS
PRODUCTS
TABLE 100 ABBOTT DIAGNOSTIC PRODUCTS
ABBVIE INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 101 ABBVIE PHARMACEUTICAL PRODUCTS
ALLERGAN (FORMERLY ACTAVIS)
BUSINESS OVERVIEW
PRODUCTS
TABLE 102 ALLERGAN PHARMACEUTICAL PRODUCTS
ALERE
BUSINESS OVERVIEW
PRODUCTS
TABLE 103 ALERE DIAGNOSTIC PRODUCTS
ALFA SCIENTIFIC DESIGNS
BUSINESS OVERVIEW
PRODUCTS
TABLE 104 ALFA SCIENTIFIC DESIGNS' DIAGNOSTIC PRODUCTS
ATLAS LINK BIOTECH CO. LTD.
BUSINESS OVERVIEW
PRODUCTS
TABLE 105 ATLAS LINK BIOTECH DIAGNOSTIC'S PRODUCTS
ASTRAZENECA
BUSINESS OVERVIEW
PRODUCTS
TABLE 106 ASTRAZENECA PHARMACEUTICAL'S PRODUCTS
AUROBIND PHARMA LTD.
BUSINESS OVERVIEW
BAXTER INTERNATIONAL INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 107 BAXTER PHARMACEUTICAL'S PRODUCTS
BAYER AG
BUSINESS OVERVIEW
PRODUCTS
TABLE 108 BAYER PHARMACEUTICAL'S PRODUCTS
BECTON DICKINSON
BUSINESS OVERVIEW
PRODUCTS
TABLE 109 BECTON DICKINSON DIAGNOSTIC'S PRODUCTS
BIO-RAD LABORATORIES
BUSINESS OVERVIEW
PRODUCTS
TABLE 110 BIO-RAD DIAGNOSTIC'S PRODUCTS
BOEHRINGER INGELHEIM GMBH
BUSINESS OVERVIEW
PRODUCTS
TABLE 111 BOEHRINGER INGELHEIM PHARMACEUTICAL'S PRODUCTS
BRISTOL-MYERS SQUIBB COMPANY
BUSINESS OVERVIEW
PRODUCTS
TABLE 112 BRISTOL-MYERS SQUIBB'S PHARMACEUTICAL PRODUCTS
CEPHEID
BUSINESS OVERVIEW
PRODUCTS
TABLE 113 CEPHEID DIAGNOSTIC'S PRODUCTS
CREATIVE PEPTIDES
BUSINESS OVERVIEW
PRODUCTS
TABLE 114 CREATIVE PEPTIDE'S DIAGNOSTIC PRODUCTS
CRUCELL NV
BUSINESS OVERVIEW
PRODUCTS
TABLE 115 CRUCELL'S VACCINE PRODUCTS
CUBIST PHARMACEUTICALS (SEE MERCK)
DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 116 DIAGNOSTIC AUTOMATION/CORTEZ DIAGNOSTICS'
DIAGNOSTIC PRODUCTS
DIASORIN
BUSINESS OVERVIEW
PRODUCTS
TABLE 117 DIASORIN DIAGNOSTIC'S PRODUCTS
FIRST DIAGNOSTIC CORP.
BUSINESS OVERVIEW
PRODUCTS
TABLE 118 FIRST DIAGNOSTIC'S PRODUCTS
FOCUS DIAGNOSTICS
BUSINESS OVERVIEW
PRODUCTS
TABLE 119 FOCUS DIAGNOSTIC'S PRODUCTS
FOREST LABORATORIES (SEE ALLERGAN)
GILEAD SCIENCES INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 120 GILEAD SCIENCE'S PHARMACEUTICAL PRODUCTS
GLAXOSMITHKLINE
BUSINESS OVERVIEW
PRODUCTS
TABLE 121 GLAXOSMITHKLINE PHARMACEUTICAL'S VACCINE PRODUCTS
HOLOGIC INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 122 HOLOGIC DIAGNOSTIC'S PRODUCTS
HOME ACCESS HEALTH CORP.
BUSINESS OVERVIEW
PRODUCTS
TABLE 123 HOME ACCESS HEALTH'S DIAGNOSTICS PRODUCTS
IDENIX PHARMACEUTICALS (SEE MERCK)
IMMUNOSTICS INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 124 IMMUNOSTIC'S DIAGNOSTIC PRODUCTS
JANSSEN THERAPEUTICS
BUSINESS OVERVIEW
PRODUCTS
TABLE 125 JANSSEN THERAPEUTIC'S PHARMACEUTICAL PRODUCTS
LUPIN PHARMACEUTICALS INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 126 LUPIN'S PHARMACEUTICAL PRODUCTS
MANGALAM DRUGS & ORGANICS LTD.
BUSINESS OVERVIEW
PRODUCTS
TABLE 127 MANGALAM'S PHARMACEUTICAL PRODUCTS
MEDMIRA INC
BUSINESS OVERVIEW
PRODUCTS
TABLE 128 MEDMIRA'S DIAGNOSTIC PRODUCTS
MELINTA THERAPEUTICS (FORMERLY RIB-X PHARMACEUTICALS)
BUSINESS OVERVIEW
MERCK & COMPANY INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 129 MERCK'S VACCINE PRODUCTS
TABLE 130 MERCK'S PHARMACEUTICAL PRODUCTS
MERIDIAN BIOSCIENCE INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 131 MERIDIAN BIOSCIENCE'S DIAGNOSTIC PRODUCTS
MYLAN PHARMACEUTICALS
BUSINESS OVERVIEW
PRODUCTS
TABLE 132 MYLAN'S PHARMACEUTICAL PRODUCTS
NOVARTIS CORP.
BUSINESS OVERVIEW
PRODUCTS
TABLE 133 NOVARTIS' DIAGNOSTIC PRODUCTS
TABLE 134 NOVARTIS' PHARMACEUTICAL PRODUCTS
ORASURE TECHNOLOGIES INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 135 ORASURE'S DIAGNOSTIC PRODUCTS
ORTHO CLINICAL DIAGNOSTICS
BUSINESS OVERVIEW
PRODUCTS
TABLE 136 ORTHO'S CLINICAL DIAGNOSTICS DIAGNOSTIC PRODUCTS
PARATEK PHARMACEUTICALS
BUSINESS OVERVIEW
PFIZER INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 137 PFIZER'S VACCINE PRODUCTS
TABLE 138 PFIZER'S PHARMACEUTICAL PRODUCTS
PRINCETON BIOMEDITECH CORP.
BUSINESS OVERVIEW
PRODUCTS
TABLE 139 PRINCETON BIOMEDICTECH'S DIAGNOSTIC PRODUCTS
PROTEIN SCIENCES CORP.
BUSINESS OVERVIEW
QUIDEL CORP.
BUSINESS OVERVIEW
PRODUCTS
TABLE 140 QUIDEL'S DIAGNOSTIC PRODUCTS
QIAGEN N.V.
BUSINESS OVERVIEW
PRODUCTS
TABLE 141 QIAGEN'S DIAGNOSTIC PRODUCTS
REMEL/THERMOFISHER SCIENTIFIC
BUSINESS OVERVIEW
PRODUCTS
TABLE 142 REMEL'S DIAGNOSTIC PRODUCTS
ROCHE LABORATORIES (HOFFMANN-LA ROCHE INC.)
BUSINESS OVERVIEW
PRODUCTS
TABLE 143 ROCHE'S DIAGNOSTIC PRODUCTS
TABLE 144 ROCHE'S PHARMACEUTICAL PRODUCTS
ROMARK LABORATORIES
BUSINESS OVERVIEW
SANDOZ
BUSINESS OVERVIEW
PRODUCTS
TABLE 145 SANDOZ'S PHARMACEUTICAL PRODUCTS
SANOFI PASTEUR
BUSINESS OVERVIEW
PRODUCTS
TABLE 146 SANOFI PASTEUR’S VACCINE PRODUCTS
SCICLONE PHARMACEUTICALS
BUSINESS OVERVIEW
PRODUCTS
TABLE 147 SCICLONE'S PHARMACEUTICAL PRODUCTS
SHANGHAI KEHUA BIO-ENGINEERING CO. LTD.
BUSINESS OVERVIEW
PRODUCTS
TABLE 148 SHANGHAI KEHUA'S DIAGNOSTIC PRODUCTS
STANDARD DIAGNOSTICS INC.
BUSINESS OVERVIEW
PRODUCTS
TABLE 149 STANDARD DIAGNOSTICS' DIAGNOSTIC PRODUCTS
TETRAPHASE PHARMACEUTICALS
THE MEDICINE COMPANY
BUSINESS OVERVIEW
PRODUCTS
TABLE 150 THE MEDICINE COMPANY'S PHARMACEUTICALS
TRINITY BIOTECH PLC
BUSINESS OVERVIEW
PRODUCTS
TABLE 151 TRINITY BIOTECH'S DIAGNOSTIC PRODUCTS
VERTEX PHARMACEUTICALS
BUSINESS OVERVIEW
PRODUCTS
TABLE 152 VERTEX'S PHARMACEUTICAL PRODUCTS
VIIV HEALTHCARE
BUSINESS OVERVIEW
PRODUCTS
TABLE 153 VIIV HEALTHCARE’S PHARMACEUTICAL PRODUCTS
ZEUS SCIENTIFIC
BUSINESS OVERVIEW
PRODUCTS
TABLE 154 ZEUS SCIENTIFIC’S DIAGNOSTIC PRODUCTS
CHAPTER 11 APPENDIX A COMPANY LISTINGS BY TYPE
TABLE 155 COMPANY LISTINGS BY TYPE, COMPANY, INDICATION AND AME

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report